FEM1AP2

Across TCGA pan-cancer cohorts, FEM1AP2 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated FEM1AP2 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher FEM1AP2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FEM1AP2 expression acts as an unfavorable survival marker, although some lineages such as BRCA and KIRP show a favorable association.

MESO, BRCA, and LUAD are the cancer types where FEM1AP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	II,III,IV	0.274	0.472	<.001	90	view →
BRCA	OS	Tertile	II,III,IV	0.948	0.876	.001	65	view →
LUAD	DFS	Tertile	IV	0.459	0.947	<.001	61	view →
HNSC	OS	Tertile	III,IV	0.192	0.587	<.001	51	view →
KIRP	DFS	Median	All	0.961	0.537	<.001	48	view →
DLBC	DFS	Tertile	IV	0.120	0.683	.001	39	view →
UCEC	DFS	Tertile	All	0.856	0.909	.017	36	view →
UVM	DFS	Tertile	III,IV	0.338	0.677	.003	34	view →
OV	OS	Tertile	II,III,IV	0.752	0.643	.011	34	view →
ACC	OS	Tertile	III,IV	0.414	0.816	.005	27	view →
LIHC	OS	Tertile	All	0.624	0.805	.005	27	view →
THCA	DFS	Tertile	II,III,IV	0.615	0.938	.007	23	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

FEM1AP2–MESO (DFS)

Open the MESO breakdown →